Emicizumab
Other Systemic Hemostatics
Sold as Hemlibra
- Drug class
- Other Systemic Hemostatics
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 9
Overview
Emicizumab is an active pharmaceutical ingredient in the Other Systemic Hemostatics group (B02BX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | November 28, 2025 |
| EU European Union | EMA | 1 | September 10, 2025 |
| CA Canada | Health Canada | 6 | September 2, 2025 |
GBUnited Kingdom· MHRA
2 products
Uses
Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency): ● with factor VIII inhibitors ● without factor VIII inhibitors who have: • severe disease (FVIII < 1%) • moderate disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding phenotype.
Hemlibra can be used in all age groups.
How to take
EUEuropean Union· EMA
1 product
Uses
Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency): ● with factor VIII inhibitors ● without factor VIII inhibitors who have: - severe disease (FVIII < 1%) - moderate disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding phenotype.
Hemlibra can be used in all age groups. 3
How to take
CACanada· Health Canada
6 products
6 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Emicizumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000310857 · revised November 28, 2025
- [2]European Medicines Agency · EMEA/H/C/004406 · revised September 10, 2025
- [3]Health Canada (DPD) · 02479621 · revised September 2, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.